Hikma has added to its portfolio of US injectables by launching dexmedetomidine hydrochloride in 0.9% sodium chloride in 200mcg/50ml and 400mcg/100ml presentations, as well as docetaxel in 20mg/ml and 80mg/4ml presentations, through its local Hikma Pharmaceuticals USA affiliate.
Hikma Introduces A Pair Of US Injectables
Builds On Strong Slate Of Launches Over Past Year
Hikma has added to its injectables portfolio in the US with the launches of dexmedetomidine and docetaxel.
More from Products
More from Generics Bulletin
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.